[{"address1": "7800 Susquehanna St.", "address2": "Suite 505", "city": "Pittsburgh", "state": "PA", "zip": "15208", "country": "United States", "phone": "412-901-0315", "website": "https://www.lipella.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.", "fullTimeEmployees": 5, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan  Kaufman M.B.A., Ph.D.", "age": 58, "title": "Co-Founder, Chairman, CEO, President, Secretary & Treasurer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 204133, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael B. Chancellor M.D.", "age": 66, "title": "Co-Founder, Chief Medical Officer & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 195833, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas  Johnston CPA", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 185000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michele  Gruber", "title": "Director of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Katie  Johnston", "title": "Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.02, "open": 4.1, "dayLow": 3.69, "dayHigh": 4.11, "regularMarketPreviousClose": 4.02, "regularMarketOpen": 4.1, "regularMarketDayLow": 3.69, "regularMarketDayHigh": 4.11, "beta": 0.297, "forwardPE": -1.2125, "volume": 214659, "regularMarketVolume": 214659, "averageVolume": 2322025, "averageVolume10days": 13144400, "averageDailyVolume10Day": 13144400, "bid": 3.86, "ask": 3.96, "bidSize": 200, "askSize": 200, "marketCap": 4690609, "fiftyTwoWeekLow": 2.21, "fiftyTwoWeekHigh": 12.0, "priceToSalesTrailing12Months": 9.700701, "fiftyDayAverage": 3.02736, "twoHundredDayAverage": 3.800105, "currency": "USD", "enterpriseValue": 3407701, "floatShares": 853799, "sharesOutstanding": 1208920, "sharesShort": 30821, "sharesShortPriorMonth": 72442, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0255, "heldPercentInsiders": 0.24348, "heldPercentInstitutions": 0.06102, "shortRatio": 0.54, "shortPercentOfFloat": 0.0312, "impliedSharesOutstanding": 1208920, "bookValue": 1.337, "priceToBook": 2.9020195, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -4263476, "trailingEps": -4.29, "forwardEps": -3.2, "lastSplitFactor": "1:8", "lastSplitDate": 1731024000, "enterpriseToRevenue": 7.048, "enterpriseToEbitda": -0.782, "52WeekChange": -0.4975, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "LIPO", "underlyingSymbol": "LIPO", "shortName": "Lipella Pharmaceuticals Inc.", "longName": "Lipella Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1671460200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d39a1b66-6fea-3b6c-8773-cda09b9e9d93", "messageBoardId": "finmb_35907207", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.88, "targetHighPrice": 10.0, "targetLowPrice": 10.0, "targetMeanPrice": 10.0, "targetMedianPrice": 10.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 1353734, "totalCashPerShare": 1.12, "ebitda": -4355956, "totalDebt": 70830, "quickRatio": 1.975, "currentRatio": 2.966, "totalRevenue": 483533, "debtToEquity": 4.855, "revenuePerShare": 0.505, "returnOnAssets": -1.0894799, "returnOnEquity": -2.3167, "grossProfits": -2521518, "freeCashflow": -2148772, "operatingCashflow": -3688044, "revenueGrowth": -0.228, "operatingMargins": -18.15644, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]